• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update

    11/1/24 4:30:16 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email
    false 0001269026 0001269026 2024-10-29 2024-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 29, 2024

     

    SINTX Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33624   84-1375299

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1885 West 2100 South

    Salt Lake City, UT 84119

    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code: (801) 839-3500

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s):   Name of each exchange on which registered:
    Common Stock, par value $0.01 per share   SINT   The NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On October 29, 2024, SINTX Technologies, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the previously executed Executive Employment Agreement (the “Agreement”) with its Chief Executive Officer and President Eric K. Olson. The amendment extended the term of the Agreement from six (6) months to twelve (12) months, subject to automatic renewals for additional six-month periods unless either the Company or Mr. Olson provides prior written notice of termination at least 30 days prior to such renewal.

     

    The Company also entered into a Change of Control Agreement (the “Change of Control Agreement”) with Mr. Olson. Among other things, the Change in Control Agreement provides that upon the consummation of a change in control, all outstanding options, restricted stock and other such rights held by the executive will fully vest. Additionally, if a change in control occurs and at any time during the one-year period following the change in control (i) we or our successor terminate the executive’s employment other than for cause (but not including termination due to the executive’s death or disability) or (ii) the executive terminates his employment for good reason, then such executive has the right to receive (i) payment consisting of a lump sum payment equal to one times his highest annual salary with us during the preceding three-year period, including the year of such termination and including bonus payments (measured on a fiscal year basis), but not including any reimbursements and amounts attributable to stock options and other non-cash compensation and (ii) continued health insurance coverage under the Company’s health plan for a period of 12 months following termination.

     

    “Change in control” is defined in the Change of Control Agreement as occurring upon: (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becoming the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities representing 50% or more of the total voting power represented by our then outstanding voting securities (excluding securities held by us or our affiliates or any of our employee benefit plans) pursuant to a transaction or a series of related transactions which our board did not approve; (ii) a merger or consolidation of our company, other than a merger or consolidation which would result in our voting securities outstanding immediately prior thereto continuing to represent at least 50% of the total voting securities or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation; (iii) the approval by our stockholders of an agreement for the sale or disposition of all or substantially all of our assets; (iv) or a change in the composition of the Board of Directors whereby individuals who were members of the Board of Directors immediately prior to the agreement cease to constitute a majority of the Board of Directors. As defined in the agreements, “cause” means: (i) the executive’s commission of a felony (other than through vicarious liability or through a motor vehicle offense); (ii) the executive’s intentional misconduct that causes material harm to the Company, provided that such misconduct is not rectifiable or remains uncorrected after written notice and a 30-day cure period; (iii) the commission by the executive of an act of fraud, embezzlement or misappropriation of funds; (iv) a material breach by the executive of any material provision of any agreement to which the executive and we are party, which breach is not cured within 30 days after our delivery to the executive of written notice of such breach; or (v) the executive’s refusal to carry out a lawful written directive from our board. “Good reason” as defined in the agreements means, without the executive’s consent: (i) a change in the principal location at which the executive performs his duties to a new work location that is at least 500 miles from the prior location; or (ii) a material change in the executive’s compensation, authority, functions, duties or responsibilities, which would cause his position with us to become of less responsibility, importance or scope than his prior position, provided, however, that such material change is not in connection with the termination of the executive’s employment with us for any reason.

     

    In the event that an officer entitled to receive or receives payment or benefit under the Change in Control Agreements described above, or under any other plan, agreement or arrangement with us, or any person whose action results in a change in control or any other person affiliated with us and it is determined that the total amount of payments will be subject to excise tax under Section 4999 of the Internal Revenue Code, or any similar successor provisions, we will be obligated to pay such officer a “gross up” payment to cover all taxes, including any excise tax and any interest or penalties imposed with respect to such taxes due to such payment. Under the Agreement, Mr. Olson’s receipt of such severance payments is subject to his execution and delivery of a general release of claims in favor of the Company.

     

    The foregoing descriptions of the Amendment and Change of Control Agreement are qualified in their entirety by reference to the full text of the Amendment and Change of Control Agreement, copies of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2024.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          SINTX Technologies, Inc.
             
    Date: November 1, 2024   By: /s/ Eric K. Olson
            Eric K. Olson
            Chief Executive Officer

     

     

    Get the next $SINT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Trask Kevin

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:45:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chairman, President and CEO Olson Eric K.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:44:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Investment Officer Honigblum Gregg R.

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:43:48 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 4–5

    SALT LAKE CITY, Utah, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride-based medical technologies, today announced that its management team will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, to be held February 4–5, 2026. The Company's participation comes at an important stage in its evolution, following a period of operational restructuring, enhanced financial discipline, and a renewed strategic focus on its core medical-technology platforms. With a more streamlined cost structure, greater visibility into its balance-sheet, and sev

    1/29/26 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies to Participate in Sidoti & Company Investor Conference

    SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that management will be presenting at Sidoti & Company's Year End Virtual Investor Conference, held December 10-11, 2025. Sidoti's Year End Virtual Investor ConferenceDates: December 10-11, 2025Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ETWebcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw To schedule a one-on-one meeting with SINTX Technologies' management team, please email KCSA Strategic Communications at [email protected]. To be added to the Sintx Technologies email distribution list, please email Si

    12/8/25 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants

    Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation ("EVONIK"), a global leader in high‑performance polymers, to manufacture the Company's proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for AI‑assisted additive manufacturing of patient‑specific implants that will be produced using equipment already in place at SINTX's U.S.-based production facility. Under the agreement, EVONIK will pr

    12/1/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    SEC Filings

    View All

    SEC Form EFFECT filed by SiNtx Technologies Inc.

    EFFECT - Sintx Technologies, Inc. (0001269026) (Filer)

    12/12/25 12:15:20 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by SiNtx Technologies Inc.

    S-3/A - Sintx Technologies, Inc. (0001269026) (Filer)

    12/9/25 5:01:07 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    12/1/25 8:35:26 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $255,350 worth of shares (65,000 units at $3.93) and was granted 53,867 shares, increasing direct ownership by 161% to 192,867 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/8/25 8:00:03 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $31,900 worth of shares (10,000 units at $3.19), increasing direct ownership by 16% to 74,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    11/10/25 8:00:06 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

    The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

    7/6/22 9:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    2/13/24 8:12:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care